RESEARCH
PUBLICATIONS
NEXTBIO COMMUNITY
-
Enzyme-catalyzed activation of anticancer prodrugs.
Authors: Martijn Rooseboom, Jan N M Commandeur, Nico P E Vermeulen
Pharmacological reviews 2004 Mar -
Design of anticancer prodrugs for reductive activation.
Authors: Yu Chen, Longqin Hu
Medicinal research reviews 2009 Jan
Thought leaders and organizations working on research involving Anticancer prodrugs.
- Taiho Pharma USA, Inc.
- Barbara Ann Karmanos Cancer Institute
- National Cancer Center, Korea
- Samsung Medical Center
- Threshold Pharmaceuticals
- Tumor Biology Center
- Boston University
- State University of New Jersey
- St. Jude Children's Research Hospital
- St. John's University
-
AFP464 in Treating Patients With Advanced Solid Tumors
conditions: Unspecified Adult Solid Tumor, Protocol Specific
interventions: AFP464 ; pharmacological study
-
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
conditions: Advanced Non-Small Cell Lung Cancer
interventions: Irinotecan ; Cisplatin ; TS-1 (S-1)
Community
-
No NextBio users were found for “Anticancer prodrugs”.
Complete your user profile with your interests, if you want others to find you within the NextBio community.
-
No NextBio groups were found for “Anticancer prodrugs”.
Be the first to start a group and share your interests with others within the NextBio community.
